Aims Endoscopic full-thickness resection (EFTR) with FTRD-system is a novel treatment
               for gastrointestinal lesions not suitable for conventional endoscopic resection. Aim
               of this retrospective single centre study was to assess its efficacy and safety.
            
               Methods Thirty-six patients (18 male, 18 female; mean age 79 years, range 51-86) were recruited
               to perform EFTR using FTRD-system: 21 colon, 9 rectum (13 residual/recurrent adenoma,
               9 non-lifting lesions, 3 incomplete resections at histology, 4 endoscopically suspected
               T1 carcinoma, 1 subepithelial lesions); 5 duodenal (4 non polypoid lesions, 1 subepithelial
               lesion); 1 gastric for early gastric cancer. Technical success (lesion reached and
               resected), R0 resection (negative lateral and deep margins), EFTR rate (all layers
               in the specimen) and adverse events (AE) were evaluated.
            
               Results Technical success was achieved in all of cases. EFTR rate was achieved in 93,3 %
               of colorectal EFTR, and in 100 % of gastro-duodenal EFTR. R0 resection rate was 93,2 %
               in colorectal EFTR and 100 % in gastro-duodenal EFTR. All histological assessments
               are presented in [table 1]. AEs occurred in 16,5 % (2 bleeding, 1 perforation, 2 post-polipectomy syndrome)
               of colorectal EFTR and in 20 % (1 bleeding) of gastro-duodenal cases: only one snare
               malfunction occurred in a colorectal case. Six month follow-up was available in 27
               cases: no evidence of residual disease or stenosis were registered.
            
               
                  Table 1 
                     Results
                     
                  
                     
                     
                        
                        | 
                              Indication, n (%)
                               | 
                     
                     
                        
                        | 
                              Colo-rectal EFTR
                               | 
                     
                     
                        
                        | Residual/recurrent adenoma | 13 (43,3 %) | 
                     
                     
                        
                        | Non-lifting lesion | 9 (3 %) | 
                     
                     
                        
                        | Suspected T1 carcinoma | 4 (13,3 %) | 
                     
                     
                        
                        | Histological R1 resection | 3 (10 %) | 
                     
                     
                        
                        | Submucosal lesion Duodenal EFTR Non-lifting lesion Submucosal lesion | 1 (3,3 %) 4 (80 %)1 (20 %) | 
                     
                     
                        
                        | 
                              Gastric EFTR
                               | 
                     
                     
                        
                        | Early gastric cancer | 1 (100 %) | 
                     
                     
                        
                        | 
                              Diameter of lesion (mm), mean, (range)
                               | 
                     
                     
                        
                        | Colo-rectal EFTR | 17 (4-32) | 
                     
                     
                        
                        | Duodenal EFTR | 21 (13-35) | 
                     
                     
                        
                        | Gastric EFTR | 20 | 
                     
                     
                        
                        | 
                              Technical success, n (%)
                               | 
                     
                     
                        
                        | Colo-rectal EFTR | 30 (100 %) | 
                     
                     
                        
                        | Duodenal EFTR | 5 (100 %) | 
                     
                     
                        
                        | Gastric EFTR | 1 (100 %) | 
                     
                     
                        
                        | 
                              EFTR resection, n (%)
                               | 
                     
                     
                        
                        | Colo-rectal EFTR | 28 (93,2 %) | 
                     
                     
                        
                        | Duodenal EFTR | 5 (100 %) | 
                     
                     
                        
                        | Gastric EFTR | 1 (100 %) | 
                     
                     
                        
                        | 
                              R0 resection, n (%)
                               | 
                     
                     
                        
                        | Colo-rectal EFTR | 28 (93,2 %) | 
                     
                     
                        
                        | Duodenal EFTR | 5 (100 %) | 
                     
                     
                        
                        | Gastric EFTR | 1 (100 %) | 
                     
                     
                        
                        | 
                              Histology, n (%)
                               | 
                     
                     
                        
                        | 
                              Colo-rectal EFTR
                               | 
                     
                     
                        
                        | High grade dysplasia adenoma | 13 (43,3 %) | 
                     
                     
                        
                        | Low grade dysplasia adenoma | 4 (13,3 %) | 
                     
                     
                        
                        | Low risk T1 carcinoma | 3 (10 %) | 
                     
                     
                        
                        | High risk T1 carcinoma | 5 (16,6 %) | 
                     
                     
                        
                        | Scar tissue | 4 (13,3 %) | 
                     
                     
                        
                        | Neuroendocrine tumor | 1 (3,3 %) | 
                     
                     
                        
                        | 
                              Duodenal EFTR
                               | 
                     
                     
                        
                        | High-grade dysplasia adenoma | 4 (80 %) | 
                     
                     
                        
                        | Neuroendocrine tumor | 1 (20 %) | 
                     
                     
                        
                        | 
                              Gastric EFTR
                               | 
                     
                     
                        
                        | Early gastric cancer | 1 (100 %) | 
                     
                     
                        
                        | 
                              Adverse events, n (%)
                               | 
                     
                     
                        
                        | 
                              Colo-rectal EFTR
                               | 
                     
                     
                        
                        | Bleeding | 2 (6,6 %) | 
                     
                     
                        
                        | Perforation | 1 (3,3 %) | 
                     
                     
                        
                        | Post-polipectomy syndrome | 2 (6,6 %) | 
                     
                     
                        
                        | 
                              Duodenal EFTR
                               | 
                     
                     
                        
                        | Bleeding | 1 (20 %) | 
                     
                     
                        
                        | 
                              Technical adverse events (colo-rectal EFTR), n (%) | 
                     
                     
                        
                        | Snare malfunction | 1 (3,3 %) | 
                     
                     
                        
                        | 
                              Six-month follow-up
                               | 
                     
                     
                        
                        | Residual disease/stenosis n (%) | 0 (0 %) | 
                     
               
             
            
            
               Conclusions Our data confirm that an appropriate patient selection is crucial to improve outcomes.
               EFTR using FTRD-system seems to be a curative, effective and safe technique for treatment
               of selected lesions that would otherwise need surgery.
            
               Citation: Soriani P, Curatolo A, Vavassori S et al. OP161 OUTCOMES IN EFTR WITH FTRD-SYSTEM:
               WHEN PATIENT SELECTION IS CRUCIAL. Endoscopy 2021; 53: S65.